A Study of the Effects of Advantage 24 on the Rectum

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000929
First received: November 2, 1999
Last updated: May 21, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm).

Much research and development is being done with chemicals that can be controlled by the receptive partner to prevent the spread of HIV and other sexually transmitted diseases (STDs). Advantage 24 currently is used in the vagina as a form of birth control. The safety of Advantage 24 is particularly important for HIV-positive men because they have a greater chance of serious reaction to Advantage 24 due to other HIV-related conditions.


Condition Intervention Phase
HIV Infections
Drug: Nonoxynol-9
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Primary Purpose: Prevention
Official Title: Phase I Rectal Microbicide Study

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 70
Study Completion Date: July 1999
Detailed Description:

Chemical barriers which can be controlled by the receptive partner to prevent transmission of HIV and other sexually transmitted diseases (STDs) are among the highest priorities for research and development. Advantage 24 is a contraceptive gel containing nonoxynol-9 (N-9). This study provides information on the safety of N-9 in a bioadhesive gel formulated for use by MSM during anal intercourse. Safety is assessed for both HIV-positive and HIV-negative men because HIV-positive men may be at increased risk for toxicity due to other HIV-related conditions.

Participants are divided into 4 cohorts depending on their serostatus and whether they are the insertive or receptive partner. Participants apply Advantage 24 once or twice a day for 5 weeks and 4 times a day for the sixth week. Check-in visits, which include a genital exam, are performed at Weeks 1, 2, 4, 5, and 7. More complete physical evaluations, including anoscopy for receptive partners and blood tests, are performed at Weeks 3, 6, and 8.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Exclusion Criteria

Co-existing Condition:

Participants with the following symptoms or conditions are excluded:

  • Positive HSV-2 serology (HIV-negative participants only).
  • Positive syphilis by Venereal Disease Research Laboratory (VDRL) serology and Fluorescent Treponemal Antibody (FTA) or Microhemagglutination Assay (MHA).

Receptive partners with the following additional symptoms or conditions are excluded:

  • Rectal gonorrhea or chlamydia by culture.
  • Active rectal inflammation, ulceration, or fissures.

Insertive partners with the following additional symptoms or conditions are excluded:

  • Penile or urethral irritation, rashes, or lesions.
  • Penile or scrotal piercing.

Concurrent Medication:

Excluded for receptive partners:

-

Anticoagulant, including warfarin and heparin.

Participants with the following prior conditions are excluded:

  • Sensitivity or irritative symptoms when using N-9 or when exposed to latex.
  • Three or more Herpes Simplex 2 Virus (HSV-2) outbreaks within 12 months prior to screening (HIV-positive participants only).
  • One or more HSV-2 outbreaks within 6 months prior to screening (HIV-positive participants only).

Receptive partners with the following additional prior conditions are excluded:

  • Diagnosed inflammatory bowel disease, ulcerative colitis, Crohn's disease, or rectal malignancy.
  • Diagnosed bleeding disorder, including hemophilia and thrombocytopenia.
  • Rectal surgery including fistulectomy.
  • Prosthetic heart valve or diagnosis of a valvular abnormality.
  • Hemorrhoidectomy within 6 months prior to screening.
  • Rectal burning, tenesmus, bleeding, or irritation in the week prior to screening.
  • Diarrhea (more than 3 stools per day) in the week prior to screening.
  • Use of rectally-inserted sex toys, practiced receptive fisting, or rectal douching in the week prior to screening.

Insertive partners with the following additional prior conditions are excluded:

Urethral burning or discharge in the week prior to screening.

Prior Medication:

Excluded for receptive partners:

Use of laxatives in the week prior to screening.

Participants meet the following criteria:

  • HIV-negative or HIV-positive; participant's partner must be the same serostatus.
  • Plan to have anal intercourse only with the study partner for the duration of the study. During all episodes in which Advantage 24 is used, one partner is exclusively insertive and the other partner is exclusively receptive.
  • Sexual partner of at least 3 months is eligible and agrees to participate.
  • Agree to use non-N-9 lubricant and condoms for all episodes of anal intercourse.
  • Avoid use of Advantage 24 for purposes other than specified by the protocol.

Receptive partners meet the following additional criteria:

  • Plan to have receptive anal intercourse with the study partner with Advantage 24 applied rectally, and using N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week).
  • Agree to apply the specified amount of Advantage 24 daily to the rectum.
  • Avoid use of laxatives, use of rectally-inserted sex toys, receptive fisting, and rectal douching.

Insertive partners meet the following additional criteria:

  • Plan to have insertive anal intercourse with the study partner with Advantage 24 applied to the glans of the penis, and using non-N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week).
  • Agree to apply the specified amount of Advantage 24 daily to the penis.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000929

Locations
United States, Washington
Univ of Washington
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Investigators
Study Chair: Connie Celum
Study Chair: Susan Buchbinder
  More Information

Additional Information:
No publications provided

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00000929     History of Changes
Other Study ID Numbers: HIVNET 008, 11715
Study First Received: November 2, 1999
Last Updated: May 21, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Sexual Partners
Homosexuality, Male
Anti-Infective Agents
Patient Compliance
Nonoxynol
Rectum

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Anti-Infective Agents
Nonoxynol
Therapeutic Uses
Pharmacologic Actions
Spermatocidal Agents
Antispermatogenic Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Male

ClinicalTrials.gov processed this record on April 22, 2014